An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa

- At least four weeks following prior standard treatment, with no evidence of disease

- Must use adequate birth control

Exclusion Criteria:

- Prior cancer vaccine therapy or concurrent participation in any other investigational
study

- A history of HIV, Hepatitis B or C, or any other acute medical condition which may
compromise patient safety or the activity of the study vaccine treatment

- A history of adverse reactions following administration of any vaccines, or a history
of hypersensitivity to any components of the study vaccine

- Women who are pregnant, intend to become pregnant, or who are breast feeding